NextCure, Inc. (NXTC) stock
Close on Nov 11, 2026Market cap $27.37MP/E –Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $27.37M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.25
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$42.75M
- EPS, diluted
- -$10.26
- Book value per share
- $2.29
- Diluted shares
- 5M
Trading
- Next earnings
- Mar 4, 2027 (estimated, after the close)
- Previous close
- $5.98
- Open
- $5.73
- Day's range
- $5.00 – $6.30
- Volume
- 93,169
- Average volume (20 days)
- 60,285
- Beta (5 years)
- 1.03
- 52-week range
- $1.55 – $15.74
- RSI (14 days)
- 51.3
- Volatility (1 year)
- 238.0%
- Relative volume
- 0.06×
- WACC
- 10.0%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NXTC | S&P 500 | Difference | NXTC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -16.7% | -2.4% | −14.3 pts | ||
| 3 months | -11.1% | -1.2% | −10.0 pts | ||
| Year to date | -57.9% | +12.3% | −70.2 pts | ||
| 1 year | -29.8% | +12.4% | −42.3 pts | ||
| 3 years | -55.1% | +78.8% | −133.9 pts | -23.4% | +21.4% |
| 5 years | -92.5% | +75.2% | −167.6 pts | -40.4% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NextCure filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Update
- Update
- Update
About NextCure
Pharmaceutical Preparations
NextCure, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing targeted therapies, particularly antibody-drug conjugates, to treat cancer patients whose disease progresses or fails to respond to existing treatments. The company focuses on biological pathways, biomarkers, and cellular interactions within the tumor microenvironment. Its lead product candidates in Phase 1 clinical development include SIM0505, an antibody-drug conjugate directed against cadherin-6, and LNCB74, an antibody-drug conjugate targeting B7-H4. Additionally, the company is seeking strategic partners to develop its other clinical oncology candidates and preclinical non-oncology programs. Because its therapeutics are investigational biologics in clinical trials, the company does not yet market commercial products to paying customers.
Company profile, executives and historyNextCure stock: common questions
What is NextCure's stock price?
NXTC closed at $5.98 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.55 and $15.74.
What is NextCure's market cap?
NextCure was worth $27.37M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NXTC's P/E ratio?
NextCure lost money over the twelve months to Jun 30, 2026 (diluted EPS -$10.26), so it has no meaningful P/E ratio.
Does NextCure pay a dividend?
No. NextCure has not paid a cash dividend over the last twelve months.
When does NextCure report earnings next?
NextCure is expected to report Q4 FY2026 results on Mar 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has NXTC stock performed over the past year?
Including dividends, NXTC returned -29.8% over the past year, against +12.4% for the S&P 500.
How many NXTC shares are sold short?
0M shares were sold short at the latest FINRA report, 5.21% of the float, or 3.0 days of average trading volume.
Who are NextCure's competitors?
Companies most similar to NextCure by business, industry and size include CNTX, PYXS, CRBP, XNCR, WHWK.
See a number that looks wrong?